The FDA granted accelerated approval to erdafitinib (Balversa, Janssen) for the treatment of adults with locally advanced or metastatic urothelial cancer with susceptible fibroblast growth factor receptor alterations that has progressed during or after platinum-containing chemotherapy.

Source link